Phase I Study of Concurrent Whole Brain Radiotherapy and Erlotinib for Multiple Brain Metastases From Non–Small-Cell Lung Cancer

2009 ◽  
Vol 74 (5) ◽  
pp. 1391-1396 ◽  
Author(s):  
Joline S.W. Lind ◽  
Frank J. Lagerwaard ◽  
Egbert F. Smit ◽  
Suresh Senan
Keyword(s):  
Lung Cancer ◽  
Brain Metastases ◽  
Phase I ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Phase I Study ◽  
Whole Brain Radiotherapy ◽  
Small Cell ◽  
Small Cell Lung ◽  
Brain Radiotherapy

Temozolomide added to whole brain radiotherapy in patients with multiple brain metastases of non-small-cell lung cancer: a multicentric Austrian phase II study

2013 ◽  
Vol 125 (15-16) ◽  
pp. 481-486 ◽  
Author(s):  
Marco Ronald Hassler ◽  
Wolfgang Pfeifer ◽  
Thomas Hendrik Knocke-Abulesz ◽  
Klaus Geissler ◽  
Gabriele Altorjai ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Phase Ii ◽  
Cell Lung Cancer ◽  
Phase Ii Study ◽  
Whole Brain Radiotherapy ◽  
Small Cell ◽  
Small Cell Lung ◽  
Brain Radiotherapy

Response of Asymptomatic Brain Metastases From Small-Cell Lung Cancer to Systemic First-Line Chemotherapy

2006 ◽  
Vol 24 (13) ◽  
pp. 2079-2083 ◽  
Author(s):  
Tatjana Seute ◽  
Pieter Leffers ◽  
Jan T. Wilmink ◽  
Guul P.M. ten Velde ◽  
Albert Twijnstra
Keyword(s):  
Lung Cancer ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Systemic Chemotherapy ◽  
Whole Brain Radiotherapy ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
Brain Radiotherapy

Purpose The purpose of this study was to investigate the radiologic response of asymptomatic brain metastases (BM) from small-cell lung cancer (SCLC) to first-line systemic chemotherapy. Patients and Methods From 1990 to 2003, 181 consecutive patients with SCLC were enrolled onto this study. Patients were examined by a neurologist on a regular basis. Magnetic resonance imaging (MRI) of the brain was performed routinely before (at diagnosis of SCLC) and after first-line systemic chemotherapy. Patients were treated with combination chemotherapy consisting of cyclophosphamide, doxorubicin, and etoposide. Clinically manifest BM were treated with whole-brain radiotherapy (WBRT). The response rate (RR) of BM was assessed by changes in the size or the number of enhanced lesions on MRI using standard criteria. Results Synchronous asymptomatic BM were found in 24 SCLC patients (13%). In six (27%) of the 22 assessable patients, the asymptomatic BM responded to systemic chemotherapy. A systemic response was found in 16 patients (73%). All patients became symptomatic during follow-up. The symptom-free survival did not differ between cranial responders and cranial nonresponders. Conclusion The RR of asymptomatic BM from SCLC to systemic chemotherapy is 27% and evidently lower than the systemic RR. Future studies should focus on the possible beneficial effect of WBRT for patients with asymptomatic synchronous BM.

Sign in / Sign up

Export Citation Format

Share Document